2024-515009-24-00招募中2 期
INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS
Clinica Universidad De Navarra3 个研究点 分布在 2 个国家目标入组 39 人开始时间: 2026年2月2日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 39
- 试验地点
- 3
- 主要终点
- Overall response rate (ORR), defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD for at least 12 weeks) as best response according to RAPNO criteria.
研究概览
简要总结
To determine if single intratumoral administration of DNX-2401 in recommended phase II dose of 5x10¹⁰ viral particles elicits tumor response in children with recurrent/refractory high grade brain tumors.
入排标准
- 年龄范围
- 0 years 至 64 years（18-64 Years, 0-17 Years）
- 接受健康志愿者
- 否
入选标准
- •The participant or participant’s parents or legally acceptable representatives (if applicable) provides written informed consent for the trial and the pediatric participant provides written assent, where applicable, based on age and country requirements.
- •Autologous Stem Cell Transplantation: patients must be ≥ 3 months post-transplant prior to entry of the study.
- •Patients must be fully recovered from all acute treatment related toxicities of all prior therapies.
- •Laboratory test: adequate hematological (platelets ≥ 100x10⁹/L, neutrophils ≥ 1.0x10⁹/L, hemoglobin ≥ 5,6 mmol/L), renal function (creatinine <1.5 times ULN) and liver function (≤3 times ULN) values.
- •Negative pregnancy test for female participants of child-bearing potential, where child-bearing potential is defined as a fertile female who is pubertal or post-pubertal and not permanently sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
- •Female participants of child-bearing potential, who are sexually active, agree to use acceptable birth control starting at informed consent and continuing for at least 120 days after DNX-2401 administration. Male participants agree to use acceptable birth control starting at informed consent and continuing for at least 90 days after DNX-2401 administration.
- •Patients with recurrent or refractory high grade malignant brain tumors (high grade glioma, embryonal CNS tumors [medulloblastomas, ATRT, EMTR, pineoblastoma], and ependymomas) diagnosis based on initial histopathological diagnosis and further clinical and radiological follow-up, in whom gross total resection is not feasible, and with a life expectancy of at least 16 weeks at the time of consent.
- •Recurrences within the radiation field will be considered if there is confirmed growth of the lesion in two consecutive MRI or if they occur at least 12 weeks after completion of radiation therapy, or if there is clear histopathological confirmation of tumor recurrence.
- •Male and female participants age ≥ 1 years and ≤ 25 years.
- •A single measurable lesion longer than 10 mm in two perpendicular diameters, considered by the investigator to be accessible for safe stereotactic biopsy and virus injection.
- •Lansky Performance Status (LPS) ≥ 60 for participants < 16 years, or Karnofsky Performance Status (KPS) ≥ 60 for participants ≥ 16 years.
- •No other chemotherapy or immunotherapy in the 4 weeks before inclusion.
- •Steroids: free off or requiring decreasing or stable corticosteroid dose (≥ 0.05 mg/kg dexamethasone daily, or equivalent for other steroids) in the 2 weeks before DNX-2401 administration.
- •Radiation: no craniospinal irradiation, total body irradiation nor focal irradiation in the 6 weeks before inclusion.
排除标准
- •Any medical or psychological condition or disease that might interfere with the subject’s ability to participate or give informed consent (if older than 16 years).
- •Life or life-attenuated vaccinations within 30 days prior to DNX-2401 administration and while participating in the study. Killed vaccines are permitted.
- •Prior participant in experimental viral therapy.
- •Inability to undergo MRI scans for any reason.
- •Pregnancy or breastfeeding.
- •Spinal location, or lesions considered risky for stereotactic injection of virus or that might favor entrance of the virus in the ventricular system.
- •Any treatment outside the allowable guidelines outlined in the inclusion criteria.
- •Severe acute infection or intercurrent medical condition including, but not limited to severe renal, hepatic, heart or bone marrow failure that based on investigator discretion do not permit inclusion in the study.
- •Subjects with immunodeficiency or autoimmune conditions, active hepatitis or known HIV. No testing for Hepatitis B, Hepatitis C and HIV is required unless mandated by local health authority.
- •Subjects with another primary malignancy.
- •Prior history of encephalitis, multiple sclerosis or other CNS infections or primary CNS disease that would interfere with evaluation.
- •Li-Fraumeni Syndrome or a known germ line deficit in the retinoblastoma gene or its related pathways.
- •Concurrent therapy with any antiviral drug or any immunosuppressive drug (except steroids).
研究组 & 干预措施
null
Test
干预措施: null (Drug)
结局指标
主要结局
Overall response rate (ORR), defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD for at least 12 weeks) as best response according to RAPNO criteria.
Overall response rate (ORR), defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD for at least 12 weeks) as best response according to RAPNO criteria.
次要结局
- PFS, OS: 6- and 12- month PFS and OS rates.
- LPS/KPS and QoL (PedsQL™ Generic Score Scale) parameters compared to baseline.
- Number of AEs and SAEs per NCI-CTCAE criteria in first 12 weeks after DNX-2401 administration.
- Time to response.
- Duration of response.
研究者
Jaime Gallego Pérez de Larraya
Scientific
Clinica Universidad De Navarra
研究点 (3)
Loading locations...
相似试验
招募中
2 期
Intratumoral DNX-2401 for High Grade Pediatric Brain TumorsEpendymomaNCT07424092Clinica Universidad de Navarra, Universidad de Navarra39
招募中
1 期
Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting StateNCT07297940Dong-A ST Co., Ltd.40
招募中
3 期
A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC2024-520386-31-00Johnson & Johnson Enterprise Innovation Inc.193
招募中
2 期
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma2024-513082-39-00Nanobiotix60
尚未招募
2 期
Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver MetastasesNCT07321847Immunophotonics, Inc.717